

Blinatumomab for minimal residual disease in adults with lymphoblastic leukemia

Blood

131, 1522-1531

DOI: [10.1182/blood-2017-08-798322](https://doi.org/10.1182/blood-2017-08-798322)

Citation Report

#	ARTICLE	IF	CITATIONS
1	“Society of Hematologic Oncology (SOHO) State of the Art Updates and Next Questions” Treatment of ALL. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 301-310.	0.2	6
2	Bispecific antibodies in haematological malignancies. Cancer Treatment Reviews, 2018, 65, 87-95.	3.4	55
3	Blinatumomab for MRD+ B-ALL: the evidence strengthens. Blood, 2018, 131, 1497-1498.	0.6	6
4	Blinatumomab facilitates complete responses. Nature Reviews Clinical Oncology, 2018, 15, 200-200.	12.5	3
5	Age matters in ALL. British Journal of Haematology, 2018, 181, 429-430.	1.2	0
6	An observational study of Chinese adults with relapsed/refractory Philadelphia-negative acute lymphoblastic leukemia. International Journal of Hematologic Oncology, 2018, 7, IJH06.	0.7	3
7	Molecular landscape and targeted therapy of acute myeloid leukemia. Biomarker Research, 2018, 6, 32.	2.8	24
8	Toward the potential cure of leukemias in the next decade. Cancer, 2018, 124, 4301-4313.	2.0	36
9	New Approaches to the Management of Adult Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2018, 36, 3504-3519.	0.8	67
10	Should immunologic strategies be incorporated into frontline ALL therapy?. Best Practice and Research in Clinical Haematology, 2018, 31, 367-372.	0.7	2
11	Is it time to routinely incorporate MRD into practice?. Best Practice and Research in Clinical Haematology, 2018, 31, 396-400.	0.7	7
13	Recent advances in the biology and treatment of B-cell acute lymphoblastic leukemia. Blood and Lymphatic Cancer: Targets and Therapy, 2018, Volume 8, 47-61.	1.2	21
14	Current and future role of bispecific T-cell engagers in pediatric acute lymphoblastic leukemia. Expert Review of Hematology, 2018, 11, 945-956.	1.0	8
15	Impact of blinatumomab on patient outcomes in relapsed/refractory acute lymphoblastic leukemia: evidence to date. Patient Related Outcome Measures, 2018, Volume 9, 329-337.	0.7	16
16	A Bortezomib-Based Protocol Induces a High Rate of Complete Remission with Minor Toxicity in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia. Acta Haematologica, 2018, 140, 209-214.	0.7	4
17	Eliminating MRD – FDA approval of blinatumomab for B-ALL in complete remission. Nature Reviews Clinical Oncology, 2018, 15, 727-728.	12.5	10
18	Antibody-based therapies in patients with acute lymphoblastic leukemia. Hematology American Society of Hematology Education Program, 2018, 2018, 9-15.	0.9	22
19	New drugs for acute myeloid leukemia inspired by genomics and when to use them. Hematology American Society of Hematology Education Program, 2018, 2018, 45-50.	0.9	38

#	ARTICLE	IF	CITATIONS
20	Prevention and treatment of relapse after stem cell transplantation with immunotherapy. Bone Marrow Transplantation, 2018, 53, 664-672.	1.3	11
21	Tracking Down and Interrogating Cancer's Holdouts. Cell, 2018, 173, 1309.	13.5	0
23	A survey of mobile technology usage and desires by caregivers of children with cancer. Pediatric Blood and Cancer, 2018, 65, e27359.	0.8	25
24	Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Acute Lymphoblastic Leukemia; Current Evidence, and Improving Outcomes Going Forward. Current Hematologic Malignancy Reports, 2018, 13, 329-340.	1.2	19
25	Rationale for Combining Bispecific T Cell Activating Antibodies With Checkpoint Blockade for Cancer Therapy. Frontiers in Oncology, 2018, 8, 285.	1.3	89
26	Acute lymphoblastic leukemia in adolescent and young adults: treat as adults or as children?. Blood, 2018, 132, 351-361.	0.6	82
27	Progress and Innovations in the Management of Adult Acute Lymphoblastic Leukemia. JAMA Oncology, 2018, 4, 1413.	3.4	69
28	Cross-sectional physician survey on the use of minimal residual disease testing in the management of pediatric and adult patients with acute lymphoblastic leukemia. Hematology, 2019, 24, 70-78.	0.7	6
29	Cancer immune therapy for lymphoid malignancies: recent advances. Seminars in Immunopathology, 2019, 41, 111-124.	2.8	15
30	Minimal Residual Disease in Acute Lymphoblastic Leukemia: Technical and Clinical Advances. Frontiers in Oncology, 2019, 9, 726.	1.3	85
31	Approach to the Adult Acute Lymphoblastic Leukemia Patient. Journal of Clinical Medicine, 2019, 8, 1175.	1.0	28
32	Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in the Era of Tyrosine Kinase Inhibitors: A Registry-Based Study of the Italian Blood and Marrow Transplantation Society (GITMO). Biology of Blood and Marrow Transplantation, 2019, 25, 2388-2397.	2.0	33
33	Transplantation in adults with relapsed/refractory acute lymphoblastic leukemia who are treated with blinatumomab from a phase 3 study. Cancer, 2019, 125, 4181-4192.	2.0	61
34	The use of bispecific antibodies to optimize the outcome of patients with acute leukemia, lymphoma and multiple myeloma after SCT. Bone Marrow Transplantation, 2019, 54, 721-726.	1.3	12
35	Advances in measurable residual disease monitoring for adult acute lymphoblastic leukemia. Advances in Cell and Gene Therapy, 2019, 2, e67.	0.6	1
36	SOHO State of the Art Update and Next Questions: Advances in the Treatment of Adult Acute Lymphoblastic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 471-479.	0.2	2
37	Updates on CAR T-cell therapy in B-cell malignancies. Immunological Reviews, 2019, 290, 39-59.	2.8	61
38	Allogeneic stem cell transplantation in the era of novel therapies for acute lymphoblastic leukaemia. Medicina Clínica (English Edition), 2019, 153, 28-34.	0.1	1

#	ARTICLE	IF	CITATIONS
39	Allogeneic Stem Cell Transplantation after Salvage Inotuzumab Ozogamicin: A Happy Ending?. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e273-e274.	2.0	1
40	Blinatumomab as a bridge to further therapy in cases of overwhelming toxicity in pediatric B-cell precursor acute lymphoblastic leukemia: Report from the Israeli Study Group of Childhood Leukemia. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27898.	0.8	22
41	How close are we to incorporating measurable residual disease into clinical practice for acute myeloid leukemia?. <i>Haematologica</i> , 2019, 104, 1532-1541.	1.7	37
42	Philadelphia chromosome-positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors. <i>American Journal of Hematology</i> , 2019, 94, 1388-1395.	2.0	26
43	How I diagnose and manage Philadelphia chromosome-like acute lymphoblastic leukemia. <i>Haematologica</i> , 2019, 104, 2135-2143.	1.7	22
44	The Role of Measurable Residual Disease (MRD) in Hematopoietic Stem Cell Transplantation for Hematological Malignancies Focusing on Acute Leukemia. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5362.	1.8	29
45	MAGIC biomarkers of acute graft-versus-host disease: Biology and clinical application. <i>Best Practice and Research in Clinical Haematology</i> , 2019, 32, 101111.	0.7	13
46	Recent advances on blinatumomab for acute lymphoblastic leukemia. <i>Experimental Hematology and Oncology</i> , 2019, 8, 28.	2.0	31
47	Can Ph-like ALL be effectively targeted?. <i>Best Practice and Research in Clinical Haematology</i> , 2019, 32, 101096.	0.7	8
48	Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients from the acute leukemia working party of the EBMT. <i>Journal of Hematology and Oncology</i> , 2019, 12, 108.	6.9	51
49	Hematological malignancies and molecular targeting therapy. <i>European Journal of Pharmacology</i> , 2019, 862, 172641.	1.7	44
50	Efficacy of tyrosine kinase inhibitors in Ph-like acute lymphoblastic leukemia harboring ABL-class rearrangements. <i>Blood</i> , 2019, 134, 1351-1355.	0.6	89
52	Blinatumomab: a novel therapy for the treatment of non-Hodgkin's lymphoma. <i>Expert Review of Hematology</i> , 2019, 12, 909-918.	1.0	7
53	Cytokine Release Syndrome With the Novel Treatments of Acute Lymphoblastic Leukemia: Pathophysiology, Prevention, and Treatment. <i>Current Oncology Reports</i> , 2019, 21, 4.	1.8	26
54	B-cell depleting immunotherapies: therapeutic opportunities and toxicities. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 497-509.	1.3	3
55	Blinatumomab for the treatment of acute lymphoblastic leukemia: an update. <i>Expert Opinion on Orphan Drugs</i> , 2019, 7, 41-46.	0.5	0
56	Bispecific Antibodies in Hematologic Malignancies: When, to Whom, and How Should Be Best Used?. <i>Current Oncology Reports</i> , 2019, 21, 17.	1.8	14
57	Novel monoclonal antibody-based treatment strategies in adults with acute lymphoblastic leukemia. <i>Therapeutic Advances in Hematology</i> , 2019, 10, 204062071984949.	1.1	18

#	ARTICLE	IF	CITATIONS
58	Bispecific antibodies: a mechanistic review of the pipeline. <i>Nature Reviews Drug Discovery</i> , 2019, 18, 585-608.	21.5	755
59	Treatment of hematological malignancies with T cell redirected bispecific antibodies: current status and future needs. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 707-720.	1.4	10
60	Molecular Residual Disease and Adjuvant Trial Design in Solid Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 6026-6034.	3.2	50
61	Recent advances in the treatment of acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2019, 60, 2606-2621.	0.6	65
62	The clinical study on treatment of CD19-directed chimeric antigen receptor-modified T cells in a case of refractory Richter syndrome. <i>Cancer Medicine</i> , 2019, 8, 2930-2941.	1.3	4
63	Acute Lymphoblastic Leukemia in the Older Adult. <i>Journal of Oncology Practice</i> , 2019, 15, 67-75.	2.5	55
64	A systematic literature review and meta-analysis of minimal residual disease as a prognostic indicator in adult B-cell acute lymphoblastic leukemia. <i>Haematologica</i> , 2019, 104, 2028-2039.	1.7	68
65	Mechanisms of resistance to CAR T cell therapy. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 372-385.	12.5	518
66	Outcomes of patients with childhood B-cell precursor acute lymphoblastic leukaemia with late bone marrow relapses: long-term follow-up of the ALLR3 open-label randomised trial. <i>Lancet Haematology</i> , 2019, 6, e204-e216.	2.2	36
67	Targeting Multiple Myeloma with AMG 424, a Novel Anti-CD38/CD3 Bispecific T-cell-recruiting Antibody Optimized for Cytotoxicity and Cytokine Release. <i>Clinical Cancer Research</i> , 2019, 25, 3921-3933.	3.2	90
68	Recent Advances in Adult Acute Lymphoblastic Leukemia. <i>Current Hematologic Malignancy Reports</i> , 2019, 14, 106-118.	1.2	21
69	Multiple Myeloma: Current Advances and Future Directions. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 255-263.	0.2	27
70	Outcome of Children With Hypodiploid Acute Lymphoblastic Leukemia: A Retrospective Multinational Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 770-779.	0.8	64
71	Taking a BiTE out of ALL: blinatumomab approval for MRD-positive ALL. <i>Blood</i> , 2019, 133, 1715-1719.	0.6	39
72	T cell-redirecting bispecific antibodies in cancer immunotherapy: recent advances. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 941-956.	1.2	33
73	Blinatumomab administered concurrently with oral tyrosine kinase inhibitor therapy is a well-tolerated consolidation strategy and eradicates measurable residual disease in adults with Philadelphia chromosome positive acute lymphoblastic leukemia. <i>Leukemia Research</i> , 2019, 79, 27-33.	0.4	54
74	Durable remissions in TCF3-HLF positive acute lymphoblastic leukemia with blinatumomab and stem cell transplantation. <i>Haematologica</i> , 2019, 104, e244-e247.	1.7	52
75	Clinical trial update on bispecific antibodies, antibody-drug conjugates, and antibody-containing regimens for acute lymphoblastic leukemia. <i>Journal of Hematology and Oncology</i> , 2019, 12, 15.	6.9	38

#	ARTICLE	IF	CITATIONS
76	Concomitant use of blinatumomab and donor lymphocyte infusion for mixed-phenotype acute leukemia: a case report with literature review. <i>Immunotherapy</i> , 2019, 11, 373-378.	1.0	22
77	Minimal residual disease level predicts outcome in adults with Ph-negative B-precursor acute lymphoblastic leukemia. <i>Hematology</i> , 2019, 24, 337-348.	0.7	48
78	Pediatric-inspired protocols in adult acute lymphoblastic leukemia: are the results bearing fruit?. <i>Hematology American Society of Hematology Education Program</i> , 2019, 2019, 17-23.	0.9	16
79	Opportunities for immunotherapy in childhood acute myeloid leukemia. <i>Blood Advances</i> , 2019, 3, 3750-3758.	2.5	25
80	The MAGIC algorithm probability is a validated response biomarker of treatment of acute graft-versus-host disease. <i>Blood Advances</i> , 2019, 3, 4034-4042.	2.5	63
81	Long-term outcome of patients with relapsed/refractory B-cell non-Hodgkin lymphoma treated with blinatumomab. <i>Blood Advances</i> , 2019, 3, 2491-2498.	2.5	68
82	Reducing minimal residual disease with blinatumomab prior to HCT for pediatric patients with acute lymphoblastic leukemia. <i>Blood Advances</i> , 2019, 3, 1926-1929.	2.5	53
83	Feasible outcome of blinatumomab followed by allogeneic hematopoietic cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage. <i>Cancer Medicine</i> , 2019, 8, 7650-7659.	1.3	8
84	Trispecific antibodies offer a third way forward for anticancer immunotherapy. <i>Nature</i> , 2019, 575, 450-451.	13.7	27
85	Adult Acute Lymphoblastic Leukemia: Treatment and Management Updates. <i>Seminars in Oncology Nursing</i> , 2019, 35, 150951.	0.7	12
86	Granulocyte Colony-Stimulating Factor-Primed Unmanipulated Haploidentical Blood and Marrow Transplantation. <i>Frontiers in Immunology</i> , 2019, 10, 2516.	2.2	36
87	Gezielte FrÃ¼herkennung und risikoadaptierte Therapie. <i>Oncology Research and Treatment</i> , 2019, 42, 2-13.	0.8	0
88	Immunotherapy in pediatric acute lymphoblastic leukemia. <i>Cancer and Metastasis Reviews</i> , 2019, 38, 595-610.	2.7	65
89	Allogeneic hematopoietic cell transplantation; the current renaissance. <i>Blood Reviews</i> , 2019, 34, 34-44.	2.8	67
90	Meeting report: Advances in minimal residual disease testing in multiple myeloma 2018. <i>Advances in Cell and Gene Therapy</i> , 2019, 2, e26.	0.6	19
91	Round optimization for improved discovery of native bispecific antibodies. <i>Methods</i> , 2019, 154, 51-59.	1.9	1
92	Hematopoietic stem cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission: a position statement of the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL) and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). <i>Bone Marrow Transplantation</i> , 2019, 54, 798-809.	1.3	106
93	Blinatumomab, a bispecific B-cell and T-cell engaging antibody, in the treatment of B-cell malignancies. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 594-602.	1.4	23

#	ARTICLE	IF	CITATIONS
94	Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: A consensus of North American experts. <i>American Journal of Hematology</i> , 2019, 94, 257-265.	2.0	99
95	Neurologic adverse events in patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab: management and mitigating factors. <i>Annals of Hematology</i> , 2019, 98, 159-167.	0.8	73
96	FDA Approval: Blinatumomab for Patients with B-cell Precursor Acute Lymphoblastic Leukemia in Morphologic Remission with Minimal Residual Disease. <i>Clinical Cancer Research</i> , 2019, 25, 473-477.	3.2	94
97	Adults with Philadelphia Chromosomeâ€œLike Acute Lymphoblastic Leukemia: Considerations for Allogeneic Hematopoietic Cell Transplantation in First Complete Remission. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e41-e45.	2.0	15
98	Successful use of blinatumomab in a patient with acute lymphoblastic leukemia and severe hepatic dysfunction. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 200-205.	0.5	3
99	Central nervous system emergencies in haematological malignancies. <i>British Journal of Haematology</i> , 2020, 189, 1028-1037.	1.2	0
100	Experience of blinatumomab salvage for patients with acute lymphoblastic leukemia presenting with isolated extramedullary relapse after previous allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2020, 55, 1469-1472.	1.3	6
101	The Quantification of Minimal Residual Disease Preâ€œand Postâ€œUnmanipulated Haploidentical Allograft by Multiparameter Flow Cytometry in Pediatric Acute Lymphoblastic Leukemia. <i>Cytometry Part B - Clinical Cytometry</i> , 2020, 98, 75-87.	0.7	18
102	Immunotherapeutic options for management of relapsed or refractory B-cell acute lymphoblastic leukemia: how to select newly approved agents?. <i>Leukemia and Lymphoma</i> , 2020, 61, 7-17.	0.6	6
103	The treatment of adolescents and young adults with acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2020, 61, 18-26.	0.6	5
104	The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphiaâ€œnegative Bâ€œcell acute lymphoblastic leukemia is a strong predictor for survival. <i>American Journal of Hematology</i> , 2020, 95, 144-150.	2.0	25
105	Population Pharmacokinetics of Blinatumomab in Pediatric and Adult Patients with Hematological Malignancies. <i>Clinical Pharmacokinetics</i> , 2020, 59, 463-474.	1.6	11
106	Real-world experience managing blinatumomab toxicities in adults with relapsed/refractory acute lymphoblastic leukemia. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 1080-1085.	0.5	2
107	Blinatumomab compared with standard of care for the treatment of adult patients with relapsed/refractory Philadelphia chromosomeâ€œpositive Bâ€œprecursor acute lymphoblastic leukemia. <i>Cancer</i> , 2020, 126, 304-310.	2.0	49
108	When a randomized controlled trial is unlikely: Propensity score analysis of blinatumomab in adults with relapsed/refractory Philadelphia chromosomeâ€œpositive Bâ€œcell acute lymphoblastic leukemia. <i>Cancer</i> , 2020, 126, 253-255.	2.0	2
109	Targeted therapy paves the way for the cure of acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2020, 188, 207-223.	1.2	20
110	Development of therapeutic antibodies for the treatment of diseases. <i>Journal of Biomedical Science</i> , 2020, 27, 1.	2.6	1,277
111	The minimal that kills: Why defining and targeting measurable residual disease is the â€œSine Qua Nonâ€œ for further progress in management of acute myeloid leukemia. <i>Blood Reviews</i> , 2020, 43, 100650.	2.8	17

#	ARTICLE	IF	CITATIONS
112	Treatment with anti CD19 chimeric antigen receptor T cells after antibody-based immunotherapy in adults with acute lymphoblastic leukemia. <i>Current Research in Translational Medicine</i> , 2020, 68, 17-22.	1.2	24
113	The face of remission induction. <i>British Journal of Haematology</i> , 2020, 188, 101-115.	1.2	3
114	Bispecific antibodies in cancer immunotherapy. <i>Current Opinion in Biotechnology</i> , 2020, 65, 9-16.	3.3	59
115	Trial designs using real-world data: The changing landscape of the regulatory approval process. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 1201-1212.	0.9	133
116	Optimizing the use of the hyperCVAD regimen: Clinical vignettes and practical management. <i>Cancer</i> , 2020, 126, 1152-1160.	2.0	29
117	Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial. <i>Leukemia Research</i> , 2020, 88, 106283.	0.4	32
119	The future of cellular immunotherapy for childhood leukemia. <i>Current Opinion in Pediatrics</i> , 2020, 32, 13-25.	1.0	13
120	Blinatumomab vs historic standard-of-care treatment for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukaemia. <i>European Journal of Haematology</i> , 2020, 104, 299-309.	1.1	17
121	Chemotherapy-free Treatment – A New Era in Acute Lymphoblastic Leukemia?. <i>New England Journal of Medicine</i> , 2020, 383, 1673-1674.	13.9	8
122	Dasatinib+Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults. <i>New England Journal of Medicine</i> , 2020, 383, 1613-1623.	13.9	279
123	The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia. , 2020, 8, e000810.		5
124	Treatment and outcome of Philadelphia chromosome-positive acute lymphoblastic leukemia in adults after relapse. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 879-891.	1.1	2
125	Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia. <i>JAMA Oncology</i> , 2020, 6, 1890.	3.4	207
126	Bispecific antibodies in acute lymphoblastic leukemia therapy. <i>Expert Review of Hematology</i> , 2020, 13, 1211-1233.	1.0	4
128	Durability of complete response after blinatumomab therapy for relapsed/refractory diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2020, 61, 2767-2770.	0.6	14
129	Monoclonal antibodies in frontline acute lymphoblastic leukemia. <i>Best Practice and Research in Clinical Haematology</i> , 2020, 33, 101226.	0.7	3
130	Recent updates for antibody therapy for acute lymphoblastic leukemia. <i>Experimental Hematology and Oncology</i> , 2020, 9, 33.	2.0	14
131	Role of blinatumomab, inotuzumab, and CAR T-cells: Which to choose and how to sequence for patients with relapsed disease. <i>Seminars in Hematology</i> , 2020, 57, 157-163.	1.8	11

#	ARTICLE	IF	CITATIONS
132	<p>Evaluating Blinatumomab for the Treatment of Relapsed/Refractory ALL: Design, Development, and Place in Therapy</p>. Blood and Lymphatic Cancer: Targets and Therapy, 2020, Volume 10, 7-20.	1.2	14
133	Immunomodulatory and clinical effects of daratumumab in Tâ€cell acute lymphoblastic leukaemia. British Journal of Haematology, 2020, 191, e28-e32.	1.2	13
134	Debate: Transplant Is Still Necessary in the Era of Targeted Cellular Therapy for Acute Lymphoblastic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 713-719.	0.2	9
135	Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts. Lancet Haematology,the, 2020, 7, e601-e612.	2.2	56
136	Phase 2 study of pembrolizumab for measurable residual disease in adults with acute lymphoblastic leukemia. Blood Advances, 2020, 4, 3239-3245.	2.5	19
137	Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial. Lancet Haematology,the, 2020, 7, e523-e533.	2.2	43
138	Blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia: results of the RIALTO trial, an expanded access study. Blood Cancer Journal, 2020, 10, 77.	2.8	65
139	Toward a cure in relapsed ALL: we must do better. Leukemia and Lymphoma, 2020, 61, 2544-2545.	0.6	0
140	Monitoring MRD in ALL: Methodologies, technical aspects and optimal time points for measurement. Seminars in Hematology, 2020, 57, 142-148.	1.8	20
141	Who Should Receive an Allogeneic Transplant in First Complete Remission?. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, S48-S51.	0.2	0
142	Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies. Annals of Hematology, 2020, 99, 2215-2229.	0.8	29
143	Immunotherapy in Pediatric B-Cell Acute Lymphoblastic Leukemia: Advances and Ongoing Challenges. Paediatric Drugs, 2020, 22, 485-499.	1.3	21
145	New Approaches to Treating Challenging Subtypes of ALL in AYA Patients. Current Hematologic Malignancy Reports, 2020, 15, 424-435.	1.2	3
146	Hematopoeitic Cell Transplantation and CAR T-Cell Therapy: Complements or Competitors?. Frontiers in Oncology, 2020, 10, 608916.	1.3	13
147	Skin-Associated B Cells in the Pathogenesis of Cutaneous Autoimmune Diseasesâ€™Implications for Therapeutic Approaches. Cells, 2020, 9, 2627.	1.8	24
148	Optimal approach to the treatment of young adults with acute lymphoblastic leukemia in 2020. Seminars in Hematology, 2020, 57, 102-114.	1.8	6
149	Recent Advances in Managing Acute Lymphoblastic Leukemia. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, 330-342.	1.8	40
150	How I treat measurable (minimal) residual disease in acute leukemia after allogeneic hematopoietic cell transplantation. Blood, 2020, 135, 1639-1649.	0.6	26

#	ARTICLE	IF	CITATIONS
151	The BiTE (bispecific Tâ€cell engager) platform: Development and future potential of a targeted immunoâ€oncology therapy across tumor types. <i>Cancer</i> , 2020, 126, 3192-3201.	2.0	116
152	Real-world outcomes of adult B-cell acute lymphocytic leukemia patients treated with blinatumomab. <i>Blood Advances</i> , 2020, 4, 2308-2316.	2.5	29
153	Biomarkers in Precision Cancer Immunotherapy: Promise and Challenges. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, e275-e291.	1.8	32
154	Measurable residual disease of acute lymphoblastic leukemia in allograft settings: how to evaluate and intervene. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 453-464.	1.1	7
155	Bispecific T-cell engaging antibodies in B-cell precursor acute lymphoblastic leukemias: focus on blinatumomab. <i>Therapeutic Advances in Hematology</i> , 2020, 11, 204062072091963.	1.1	4
156	Immunotherapy in Hematologic Malignancies. <i>Current Oncology</i> , 2020, 27, 124-131.	0.9	20
157	Using Pharmacology to Squeeze the Life Out of Childhood Leukemia, and Potential Strategies to Achieve Breakthroughs in Medulloblastoma Treatment. <i>Pharmacological Reviews</i> , 2020, 72, 668-691.	7.1	6
158	IConMHC: a deep learning convolutional neural network model to predict peptide and MHC-I binding affinity. <i>Immunogenetics</i> , 2020, 72, 295-304.	1.2	4
159	Blinatumomab or Inotuzumab Ozogamicin as Bridge to Allogeneic Stem Cell Transplantation for Relapsed or Refractory B-lineage Acute Lymphoblastic Leukemia: A Retrospective Single-Center Analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e724-e733.	0.2	7
160	Polatuzumab vedotin for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 831-839.	1.4	9
161	Personalized therapy in pediatric high-risk B-cell acute lymphoblastic leukemia. <i>Therapeutic Advances in Hematology</i> , 2020, 11, 204062072092757.	1.1	13
162	Open-Label, phase 2 study of blinatumomab as second salvage therapy in adults with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2020, 61, 2103-2112.	0.6	55
163	Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions. <i>Journal of Hematology and Oncology</i> , 2020, 13, 70.	6.9	100
164	Evaluation and management of measurable residual disease in acute lymphoblastic leukemia. <i>Therapeutic Advances in Hematology</i> , 2020, 11, 204062072091002.	1.1	25
165	The Many Facets of CD38 in Lymphoma: From Tumorâ€Microenvironment Cell Interactions to Acquired Resistance to Immunotherapy. <i>Cells</i> , 2020, 9, 802.	1.8	23
166	T cell-engaging therapies â€ BiTEs and beyond. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 418-434.	12.5	296
167	Recent Advances in the Management of Acute Lymphoblastic Leukaemia. <i>Current Treatment Options in Oncology</i> , 2020, 21, 23.	1.3	16
168	Frontline Blinatumomab in Older Adults with Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. <i>Pharmaceuticals</i> , 2020, 13, 124.	1.7	5

#	ARTICLE	IF	CITATIONS
169	Advances in Supportive Care for Acute Lymphoblastic Leukemia. Current Hematologic Malignancy Reports, 2020, 15, 276-293.	1.2	8
170	Acute lymphoblastic leukemia: From aminopterin to CAR T cells. Medicina Clínica (English Edition), 2020, 154, 269-274.	0.1	1
171	Curative outcomes following blinatumomab in adults with minimal residual disease B-cell precursor acute lymphoblastic leukemia. Leukemia and Lymphoma, 2020, 61, 2665-2673.	0.6	44
172	Blinatumomab for Acute Lymphoblastic Leukemia: The First Bispecific T-Cell Engager Antibody to Be Approved by the EMA for Minimal Residual Disease. Oncologist, 2020, 25, e709-e715.	1.9	11
173	Outcomes of Allogeneic Hematopoietic Cell Transplantation after Salvage Therapy with Blinatumomab in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia. Biology of Blood and Marrow Transplantation, 2020, 26, 1084-1090.	2.0	19
174	Toxicities of novel therapies for hematologic malignancies. Expert Review of Hematology, 2020, 13, 241-257.	1.0	2
175	Serial evaluation of CD19 surface expression in pediatric B-cell malignancies following CD19-targeted therapy. Leukemia, 2020, 34, 3064-3069.	3.3	33
176	Summary of a workshop on preclinical and translational safety assessment of CD3 bispecifics. Journal of Immunotoxicology, 2020, 17, 67-85.	0.9	30
177	Harnessing immunotherapy for pediatric T-cell malignancies. Expert Review of Clinical Immunology, 2020, 16, 361-371.	1.3	12
178	Hematopoietic stem cell transplantation for blood cancers in the era of precision medicine and immunotherapy. Cancer, 2020, 126, 1837-1855.	2.0	20
179	Practical guidance for the management of acute lymphoblastic leukemia in the adolescent and young adult population. Therapeutic Advances in Hematology, 2020, 11, 204062072090353.	1.1	23
180	Safety and efficacy of blinatumomab: a real world data. Annals of Hematology, 2020, 99, 835-838.	0.8	19
181	Harnessing T Cells to Target Pediatric Acute Myeloid Leukemia: CARs, BiTEs, and Beyond. Children, 2020, 7, 14.	0.6	13
182	<p>>Blinatumomab for the Treatment of Adult B-Cell Acute Lymphoblastic Leukemia: Toward a New Era of Targeted Immunotherapy</p></p>. Biologics: Targets and Therapy, 2020, Volume 14, 23-34.	3.0	23
183	A pediatric regimen for adolescents and young adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: Results of the ALLRE08 PETHEMA trial. Cancer Medicine, 2020, 9, 2317-2329.	1.3	13
184	Management of toxicities associated with novel immunotherapy agents in acute lymphoblastic leukemia. Therapeutic Advances in Hematology, 2020, 11, 204062071989989.	1.1	31
185	Monitoring minimal residual/relapsing disease after allogeneic haematopoietic stem cell transplantation in adult patients with acute lymphoblastic leukaemia. Bone Marrow Transplantation, 2020, 55, 1410-1420.	1.3	7
186	Top 10 Challenges in Cancer Immunotherapy. Immunity, 2020, 52, 17-35.	6.6	1,177

#	ARTICLE	IF	CITATIONS
187	Treatment of Frail Older Adults and Elderly Patients With Philadelphia Chromosome-negative Acute Lymphoblastic Leukemia: Results of a Prospective Trial With Minimal Chemotherapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e513-e522.	0.2	5
188	Hematopoietic Cell Transplantation for Philadelphia Chromosome Negative Adult Acute Lymphoblastic Leukemia in the Modern Era of Immune Therapy. <i>Current Hematologic Malignancy Reports</i> , 2020, 15, 187-193.	1.2	1
189	Characteristics and Trends of Adult Acute Lymphoblastic Leukemia in a Large, Public Safety-Net Hospital. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e320-e327.	0.2	5
190	Blinatumomab for infant acute lymphoblastic leukemia. <i>Blood</i> , 2020, 135, 1501-1504.	0.6	43
191	Real-World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated With Inotuzumab Ozogamicin. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 556-560.e2.	0.2	12
192	Adhesion of T Cells to Endothelial Cells Facilitates Blinatumomab-Associated Neurologic Adverse Events. <i>Cancer Research</i> , 2020, 80, 91-101.	0.4	54
193	How I treat adults with advanced acute lymphoblastic leukemia eligible for CD19-targeted immunotherapy. <i>Blood</i> , 2020, 135, 804-813.	0.6	34
194	Treating Leukemia in the Time of COVID-19. <i>Acta Haematologica</i> , 2021, 144, 132-145.	0.7	57
195	Characterization of relapse patterns in patients with acute lymphoblastic leukemia treated with blinatumomab. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 821-826.	0.5	7
196	Measurable residual disease in hematopoietic stem cell transplantation-eligible patients with acute myeloid leukemia: clinical significance and promising therapeutic strategies. <i>Leukemia and Lymphoma</i> , 2021, 62, 8-31.	0.6	4
197	Blinatumomab+â€‰ponatinib for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia in adults. <i>Leukemia and Lymphoma</i> , 2021, 62, 620-629.	0.6	36
198	Chemotherapy or allogeneic transplantation in high-risk Philadelphia chromosomeâ€‰negative adult lymphoblastic leukemia. <i>Blood</i> , 2021, 137, 1879-1894.	0.6	48
199	International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials. <i>Leukemia</i> , 2021, 35, 18-30.	3.3	69
200	Acute Leukemias. <i>Hematologic Malignancies</i> , 2021, , .	0.2	2
201	Promising genes and variants to reduce chemotherapy adverse effects in acute lymphoblastic leukemia. <i>Translational Oncology</i> , 2021, 14, 100978.	1.7	6
202	AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 1526-1537.	3.2	86
203	Adolescent and young adult acute lymphoblastic leukemia. Final results of the phase <sc>II</sc> pediatricâ€‰like <sc>GIMEMA LAL</sc>â€‰1308 trial. <i>American Journal of Hematology</i> , 2021, 96, 292-301.	2.0	21
204	Allogeneic HCT for adults with B-cell precursor acute lymphoblastic leukemia harboring IKZF1 gene mutations. A study by the Acute Leukemia Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 1047-1055.	1.3	2

#	ARTICLE	IF	CITATIONS
205	The management of hematologic malignancies during the COVID-19 pandemic. Expert Opinion on Pharmacotherapy, 2021, 22, 565-582.	0.9	9
206	Role of immunoglobulin and antibodies in disease management. International Journal of Biological Macromolecules, 2021, 169, 28-38.	3.6	41
207	Side-effect management of chimeric antigen receptor (CAR) T-cell therapy. Annals of Oncology, 2021, 32, 34-48.	0.6	231
208	Clinical utilization of blinatumomab and inotuzumab immunotherapy in children with relapsed or refractory B-acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2021, 68, e28718.	0.8	30
209	Tumor-intrinsic and -extrinsic determinants of response to blinatumomab in adults with B-ALL. Blood, 2021, 137, 471-484.	0.6	70
210	Fatal capillary leak syndrome in a child with acute lymphoblastic leukemia treated with moxetumomab pasudotox for pre-transplant minimal residual disease reduction. Pediatric Blood and Cancer, 2021, 68, e28574.	0.8	2
211	Concomitant use of a dual Src/ABL kinase inhibitor eliminates the in vitro efficacy of blinatumomab against Ph+ ALL. Blood, 2021, 137, 939-944.	0.6	22
212	Liquid biopsy enters the clinic – implementation issues and future challenges. Nature Reviews Clinical Oncology, 2021, 18, 297-312.	12.5	609
213	Acute Lymphoblastic Leukemia. , 2021, , 251-270.		0
214	Early autologous and allogeneic peripheral blood stem cell transplantation for adult patients with acute B and T cell precursor neoplasms: a 12-year single center experience. Annals of Hematology, 2021, 100, 809-816.	0.8	2
215	Bispecific antibody target pair discovery by high-throughput phenotypic screening using in vitro combinatorial Fab libraries. MAbs, 2021, 13, 1859049.	2.6	5
216	Overcoming the challenges associated with CD3+ T-cell redirection in cancer. British Journal of Cancer, 2021, 124, 1037-1048.	2.9	42
217	Therapeutic Approaches to Employ Monoclonal Antibody for Cancer Treatment. Advances in Medical Diagnosis, Treatment, and Care, 2021, , 42-88.	0.1	0
218	CAR T cells better than BiTEs. Blood Advances, 2021, 5, 602-606.	2.5	17
219	Immune checkpoint inhibition in myeloid malignancies: Moving beyond the PD-1/PD-L1 and CTLA-4 pathways. Blood Reviews, 2021, 45, 100709.	2.8	24
220	BiTEs better than CAR T cells. Blood Advances, 2021, 5, 607-612.	2.5	59
221	Immunophenotypic Profile of Blast Cells as a Marker for Diagnosis of Relapsed Children Acute Lymphoblastic Leukemia. Ukraïns'kij Åurnal Medicini B-olog-Å Ta Sportu, 2021, 6, 56-64.	0.0	0
222	DARTs point the way forward in AML. Blood, 2021, 137, 720-721.	0.6	1

#	ARTICLE	IF	CITATIONS
223	The impact of phenotypic heterogeneity of tumour cells on treatment and relapse dynamics. <i>PLoS Computational Biology</i> , 2021, 17, e1008702.	1.5	11
224	Allogeneic hematopoietic stem cell transplantation for adult patients with t(4;11)(q21;q23) KMT2A/AFF1 B-cell precursor acute lymphoblastic leukemia in first complete remission: impact of pretransplant measurable residual disease (MRD) status. An analysis from the Acute Leukemia Working Party of the EBMT. <i>Leukemia</i> , 2021, 35, 2232-2242.	3.3	6
225	Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia. , 2021, 9, e002026.		11
226	Minimal Residual Disease in Acute Lymphoblastic Leukemia. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2021, 42, 071-076.	0.1	1
227	Blinatumomab-induced T cell activation at single cell transcriptome resolution. <i>BMC Genomics</i> , 2021, 22, 145.	1.2	11
228	Cytokine gene polymorphisms are associated with response to blinatumomab in B-cell acute lymphoblastic leukemia. <i>European Journal of Haematology</i> , 2021, 106, 851-858.	1.1	2
229	Anti-CD117 immunotherapy to eliminate hematopoietic and leukemia stem cells. <i>Experimental Hematology</i> , 2021, 95, 31-45.	0.2	15
230	Have any strategies in Ph-like ALL been shown to be effective?. <i>Best Practice and Research in Clinical Haematology</i> , 2021, 34, 101242.	0.7	10
231	T-cell-based Immunotherapies for Haematological Cancers, Part A: A SWOT Analysis of Immune Checkpoint Inhibitors (ICIs) and Bispecific T-Cell Engagers (BiTEs). <i>Anticancer Research</i> , 2021, 41, 1123-1141.	0.5	6
232	Blinatumomab for Treatment of Children With High-risk Relapsed B-Cell Acute Lymphoblastic Leukemia. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 830.	3.8	11
233	Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 843.	3.8	166
234	Blinatumomab as first salvage versus second or later salvage in adults with relapsed/refractory B-cell precursor acute lymphoblastic leukemia: Results of a pooled analysis. <i>Cancer Medicine</i> , 2021, 10, 2601-2610.	1.3	8
235	Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 833.	3.8	177
236	Molecular remission after combination therapy with blinatumomab and ponatinib with relapsed/refractory Philadelphia chromosome-positive acute lymphocytic leukemia: two case reports. <i>Journal of Medical Case Reports</i> , 2021, 15, 164.	0.4	4
237	PD-1 Inhibition Enhances Blinatumomab Response in a UCB/PDX Model of Relapsed Pediatric B-Cell Acute Lymphoblastic Leukemia. <i>Frontiers in Oncology</i> , 2021, 11, 642466.	1.3	14
238	Blinatumomab as a successful and safe therapy in Down syndrome patients with relapsed/refractory B-cell precursor acute lymphoblastic leukaemia: Case reports and literature review. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29044.	0.8	7
239	Personalized patient care with aggressive hematological malignancies in non-responders to first-line treatment. <i>Expert Review of Precision Medicine and Drug Development</i> , 2021, 6, 203-215.	0.4	2
240	Advances in the Diagnosis and Treatment of Pediatric Acute Lymphoblastic Leukemia. <i>Journal of Clinical Medicine</i> , 2021, 10, 1926.	1.0	86

#	ARTICLE	IF	CITATIONS
241	Measurable Residual Disease Assessment and Allogeneic Transplantation as Consolidation Therapy in Adult Acute Lymphoblastic Leukemia in Colombia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e365-e372.	0.2	3
242	Activity of blinatumomab in lymphoblastic leukemia with impaired T-cell immunity due to congenital immunodeficiency. <i>Blood Advances</i> , 2021, 5, 2153-2155.	2.5	8
243	CD19 CAR-T cell treatment conferred sustained remission in B-ALL patients with minimal residual disease. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 3501-3511.	2.0	12
244	Multi-institutional study evaluating clinical outcome with allogeneic hematopoietic stem cell transplantation after blinatumomab in patients with B-cell acute lymphoblastic leukemia: real-world data. <i>Bone Marrow Transplantation</i> , 2021, 56, 1998-2004.	1.3	11
245	Has MRD graduated from its adolescence in ALL?. <i>Blood</i> , 2021, 137, 1846-1847.	0.6	0
246	MRD-Based Therapeutic Decisions in Genetically Defined Subsets of Adolescents and Young Adult Philadelphia-Negative ALL. <i>Cancers</i> , 2021, 13, 2108.	1.7	5
247	Development of a bispecific immune engager using a recombinant malaria protein. <i>Cell Death and Disease</i> , 2021, 12, 353.	2.7	5
248	Rapid Progress in Immunotherapies for Multiple Myeloma: An Updated Comprehensive Review. <i>Cancers</i> , 2021, 13, 2712.	1.7	13
249	T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments. <i>Leukemia</i> , 2021, 35, 1843-1863.	3.3	123
250	Efficacy of blinatumomab for MRD relapse in ALL post allogenic HCT. <i>Leukemia Research</i> , 2021, 104, 106579.	0.4	4
251	The use of intrathecal chemotherapy and dexamethasone for secondary prevention of blinatumomab-related neurotoxicity. <i>Current Research in Translational Medicine</i> , 2021, 69, 103285.	1.2	7
252	Mechanisms of Cardiovascular Toxicities Associated With Immunotherapies. <i>Circulation Research</i> , 2021, 128, 1780-1801.	2.0	48
253	Relationship of genetic deviations with laboratory indicators of peripheral blood and bone marrow in children with acute lymphoblastic leukemia. <i>Bukovinian Medical Herald</i> , 2021, 25, 11-18.	0.1	0
254	Bispecific Antibodies: From Research to Clinical Application. <i>Frontiers in Immunology</i> , 2021, 12, 626616.	2.2	129
255	The landscape of bispecific T cell engager in cancer treatment. <i>Biomarker Research</i> , 2021, 9, 38.	2.8	90
256	Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies. <i>Journal of Hematology and Oncology</i> , 2021, 14, 75.	6.9	107
257	Expanding the Toolbox of Adoptive Cell Immunotherapy. <i>Journal of Clinical Oncology</i> , 2021, 39, 1479-1482.	0.8	0
258	BiTEs, DARTs, BiKEs and TriKEs—Are Antibody Based Therapies Changing the Future Treatment of AML?. <i>Life</i> , 2021, 11, 465.	1.1	21

#	ARTICLE	IF	CITATIONS
259	The Potential Role of the Intestinal Microenvironment and Individual Microbes in the Immunobiology of Chimeric Antigen Receptor T-Cell Therapy. <i>Frontiers in Immunology</i> , 2021, 12, 670286.	2.2	16
260	Efficacy and tolerability of a modified pediatric-inspired intensive regimen for acute lymphoblastic leukemia in older adults. <i>EJHaem</i> , 2021, 2, 413-420.	0.4	4
261	Relapsed <i>Babesia microti</i> Infection Following Allogeneic Hematopoietic Cell Transplantation in a Patient With B-cell Acute Lymphoblastic Leukemia: Case Report and Review of the Literature. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab323.	0.4	6
262	Focused CRISPR-Cas9 genetic screening reveals USO1 as a vulnerability in B-cell acute lymphoblastic leukemia. <i>Scientific Reports</i> , 2021, 11, 13158.	1.6	10
263	T Cell Defects and Immunotherapy in Chronic Lymphocytic Leukemia. <i>Cancers</i> , 2021, 13, 3255.	1.7	6
264	Optimizing the treatment of acute lymphoblastic leukemia in younger and older adults: new drugs and evolving paradigms. <i>Leukemia</i> , 2021, 35, 3044-3058.	3.3	29
265	Investigational immunotherapy targeting CD19 for the treatment of acute lymphoblastic leukemia. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 773-784.	1.9	8
266	Targeted Therapy in Acute Lymphoblastic Leukaemia. <i>Journal of Personalized Medicine</i> , 2021, 11, 715.	1.1	8
267	Modified Therapeutic Antibodies: Improving Efficacy. <i>Engineering</i> , 2021, 7, 1529-1540.	3.2	3
268	Potential Role of CD47-Directed Bispecific Antibodies in Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2021, 12, 686031.	2.2	19
269	Therapeutic strategies, including allogeneic stem cell transplantation, to overcome relapsed/refractory adult T-cell acute lymphoblastic leukemia. <i>Expert Review of Hematology</i> , 2021, 14, 765-775.	1.0	8
270	The Care of the Leukemic Patients in Times of SARS-CoV-2. <i>Current Oncology Reports</i> , 2021, 23, 114.	1.8	2
271	Rapid and Deep Remission Induced by Blinatumomab for CD19-Positive Chronic Myeloid Leukemia in Lymphoid Blast Phase. <i>JCO Precision Oncology</i> , 2021, 5, 1141-1146.	1.5	6
272	Trials and Tribulations in the Frontline Treatment of Older Adults with Acute Myeloid Leukemia. <i>Hemato</i> , 2021, 2, 515-544.	0.2	0
273	Antibody and cellular immunotherapies for acute lymphoblastic leukemia in adults. <i>Leukemia and Lymphoma</i> , 2021, 62, 3333-3347.	0.6	2
274	Should Undetectable Minimal Residual Disease Be the Goal of Chronic Lymphocytic Leukemia Therapy?. <i>Hematology/Oncology Clinics of North America</i> , 2021, 35, 775-791.	0.9	8
275	Strong expansion of normal CD19-negative B-cell precursors after the use of blinatumomab in the frontline therapy of acute lymphoblastic leukaemia in children. <i>British Journal of Haematology</i> , 2022, 196, .	1.2	6
276	Refractory DLBCL: Challenges and Treatment. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 140-148.	0.2	8

#	ARTICLE	IF	CITATIONS
277	The promise of bispecific antibodies: Clinical applications and challenges. <i>Cancer Treatment Reviews</i> , 2021, 99, 102240.	3.4	28
278	Optimal Timing of Blinatumomab for the Treatment of B-Lymphoblastic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S99-S101.	0.2	0
279	Novel Transplant and Post-Transplant Options in ALL. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S7-S9.	0.2	0
280	The promise and perils of immunotherapy. <i>Blood Advances</i> , 2021, 5, 3709-3725.	2.5	23
281	Bispecific antibodies for non-Hodgkinâ€™s lymphomas and multiple myeloma. <i>Drugs in Context</i> , 2021, 10, 1-12.	1.0	6
282	Acute Lymphoblastic Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 1079-1109.	2.3	96
283	Different Kinetics and Risk Factors for Isolated Extramedullary Relapse after Allogeneic Hematopoietic Stem Cell Transplantation in Children with Acute Leukemia. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 859.e1-859.e10.	0.6	4
284	A Systematic Review of Blinatumomab in the Treatment of Acute Lymphoblastic Leukemia: Engaging an Old Problem With New Solutions. <i>Annals of Pharmacotherapy</i> , 2021, 55, 1236-1253.	0.9	6
285	Targeting CDK7 suppresses super enhancer-linked inflammatory genes and alleviates CAR T cell-induced cytokine release syndrome. <i>Molecular Cancer</i> , 2021, 20, 5.	7.9	12
287	Blinatumomab in pediatric patients with relapsed/refractory Bâ€cell precursor acute lymphoblastic leukemia. <i>European Journal of Haematology</i> , 2021, 106, 473-483.	1.1	38
288	Novel Therapies in the Treatment of Adult Acute Lymphoblastic Leukemia. <i>Current Hematologic Malignancy Reports</i> , 2020, 15, 294-304.	1.2	17
289	Investigation of the effect of salt additives in Protein L affinity chromatography for the purification of tandem single-chain variable fragment bispecific antibodies. <i>MAbs</i> , 2020, 12, 1718440.	2.6	23
290	Navigating the nexus of MRD and novel agents in ALL. <i>Hematology American Society of Hematology Education Program</i> , 2019, 2019, 9-16.	0.9	2
291	Moving immunotherapy into the front line in ALL. <i>Hematology American Society of Hematology Education Program</i> , 2019, 2019, 209-217.	0.9	13
292	Philadelphia Chromosomeâ€™Negative B-Cell Acute Lymphoblastic Leukemia in Adolescents and Young Adults. <i>JCO Oncology Practice</i> , 2020, 16, 231-238.	1.4	4
293	New monoclonal antibodies and tyrosine kinase inhibitors in B-cell acute lymphoblastic leukemia. <i>Minerva Medica</i> , 2020, 111, 478-490.	0.3	4
294	Relapse and Resistance to CAR-T Cells and Blinatumomab in Hematologic Malignancies. <i>Clinical Hematology International</i> , 2019, 1, 79.	0.7	15
295	Treatment of Adult Patients with Relapsed/Refractory B-Cell Philadelphia-Negative Acute Lymphoblastic Leukemia. <i>Clinical Hematology International</i> , 2019, 1, 85-93.	0.7	12

#	ARTICLE	IF	CITATIONS
296	Pediatric acute lymphoblastic leukemia. <i>Haematologica</i> , 2020, 105, 2524-2539.	1.7	313
297	Why Immunotherapy Fails in Multiple Myeloma. <i>Hemato</i> , 2021, 2, 1-42.	0.2	5
298	Blood and Bone Marrow Transplantation in India: Past, Present, and Future. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2020, 41, 308-311.	0.1	8
299	Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2019. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 414-423.	2.3	44
300	Pediatric Acute Lymphoblastic Leukemia, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 81-112.	2.3	102
301	Management of adverse effects of new monoclonal antibody treatments in acute lymphoblastic leukemia. <i>Drugs in Context</i> , 2020, 9, 1-15.	1.0	5
302	Integrative transcriptome data mining for identification of core lncRNAs in breast cancer. <i>PeerJ</i> , 2019, 7, e7821.	0.9	30
303	Current and Emerging Therapies for Acute Myeloid Leukemia. <i>Cancer Treatment and Research</i> , 2021, 181, 57-73.	0.2	2
304	An MRD-stratified pediatric protocol is as deliverable in adolescents and young adults as in children with ALL. <i>Blood Advances</i> , 2021, 5, 5574-5583.	2.5	6
305	The cure of leukemia through the optimist's prism. <i>Cancer</i> , 2022, 128, 240-259.	2.0	17
306	Has Ph-like ALL Superseded Ph+ ALL as the Least Favorable Subtype?. <i>Best Practice and Research in Clinical Haematology</i> , 2021, 34, 101331.	0.7	6
307	Extramedullary disease relapse and progression after blinatumomab therapy for treatment of acute lymphoblastic leukemia. <i>Cancer</i> , 2022, 128, 529-535.	2.0	17
308	Discovery of targeted expression data for novel antibody-based and chimeric antigen receptor-based therapeutics in soft tissue sarcomas using RNA-sequencing: clinical implications. <i>Current Problems in Cancer</i> , 2021, 45, 100794.	1.0	4
309	Application of Next-Generation Sequencing-Based Mutational Profiling in Acute Lymphoblastic Leukemia. <i>Current Hematologic Malignancy Reports</i> , 2021, 16, 394-404.	1.2	2
310	Next-Generation Sequencing for Measurable Residual Disease Assessment in Acute Leukemia. <i>Advances in Molecular Pathology</i> , 2021, 4, 49-63.	0.2	2
311	Game changers in pediatric cancer. <i>Journal of Community and Supportive Oncology</i> , 2018, 16, e210-e216.	0.1	0
312	Resistance to Bispecific T-Cell Engagers and Bispecific Antibodies. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2019, , 181-192.	0.1	2
313	Blinatumomab in the Treatment of Acute Lymphoblastic Leukemia: Russian Multicenter Clinical Trial. <i>Klinicheskaya Onkogematologiya/Clinical Oncohematology</i> , 2019, 12, 45-53.	0.1	2

#	ARTICLE	IF	CITATIONS
314	El trasplante alogéneo de progenitores hematopoyéticos en la era de las nuevas terapias en la leucemia linfoblástica aguda. Medicina Clínica, 2019, 153, 28-34.	0.3	2
315	Clinical Experience with Bispecific T Cell Engagers. Recent Results in Cancer Research, 2020, 214, 71-91.	1.8	2
316	Adolescents and Young Adults with Acute Lymphoblastic Leukemia. , 2020, , 109-122.		0
317	Management of Recurrent Acute Lymphoblastic Leukemia With T-Cell Engagement: CAR T, BiTEs, and Beyond. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 1448-1450.	2.3	0
318	Opportunities for immunotherapy in childhood acute myeloid leukemia. Hematology American Society of Hematology Education Program, 2019, 2019, 218-225.	0.9	1
320	Immunotherapy for Hematological Malignancies “ Now and Future “.. The Journal of the Japanese Society of Internal Medicine, 2020, 109, 301-307.	0.0	0
321	Leucemia aguda linfoblástica: de la aminopterina a las células CAR T. Medicina Clínica, 2020, 154, 269-274.	0.3	1
322	Will immunotherapy lead to a breakthrough in the treatment of older adults with ALL?. Best Practice and Research in Clinical Haematology, 2021, 34, 101319.	0.7	1
323	Detection of measurable residual disease in adults with acute leukaemia. Gematologiya i Transfuziologiya, 2020, 65, 460-472.	0.1	4
324	Neue Arzneimittel 2019. , 2020, , 43-150.		2
325	Cancer Immunotherapy Confers a Global Benefit. , 2020, , 1-48.		0
326	Treatment of Acute Lymphoid Leukemia Refractory to Classic First-Line and Rescue Protocols. International Journal of Hematology-Oncology and Stem Cell Research, 0, , .	0.3	0
327	Immunotherapy in Pediatric Hematologic Malignant Neoplasms. Clinical Pediatric Hematology-Oncology, 2020, 27, 14-21.	0.0	0
328	New approaches to the treatment of older adults with acute lymphoblastic leukemia. Seminars in Hematology, 2020, 57, 122-129.	1.8	3
329	Hematopoietic Cell Transplantation (HCT) for Acute Lymphoblastic Leukemia (ALL). Hematologic Malignancies, 2021, , 193-204.	0.2	0
330	Minimal or Measurable Residual Disease in Acute Lymphoblastic Leukemia. Hematologic Malignancies, 2021, , 205-218.	0.2	0
332	Management of Relapsed and Refractory ALL. Hematologic Malignancies, 2021, , 277-289.	0.2	0
333	Immuno-Target Therapy for Relapsed or Refractory Acute Lymphoblastic Leukemia. Korean Journal of Medicine, 2020, 95, 320-324.	0.1	0

#	ARTICLE	IF	CITATIONS
335	To Transplant or Not? Weighing the Risks of Blinatumomab Prior to Hematopoietic Stem Cell Transplant in Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e209-e210.	2.0	0
336	Advances in biology of acute lymphoblastic leukemia (ALL) and therapeutic implications. <i>American Journal of Blood Research</i> , 2018, 8, 29-56.	0.6	21
337	Treatment of Acute Lymphoid Leukemia Refractory to Classic First-Line and Rescue Protocols. <i>International Journal of Hematology-Oncology and Stem Cell Research</i> , 2020, 14, 123-126.	0.3	0
338	Acute lymphoblastic leukaemia (ALL) things come to those who wait: 60 years of progress in the treatment of adult ALL. <i>British Journal of Haematology</i> , 2020, 191, 558-561.	1.2	1
340	How I Use Measurable Residual Disease in the Clinical Management of Adult Acute Lymphoblastic Leukemia. <i>Clinical Hematology International</i> , 2021, 3, 130.	0.7	6
341	BiTEs Expressed by an Oncolytic Herpes Simplex Virus Type 2 Can Transform Heterologous T Cells Into Uniform Tumor Killer Cells. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
342	Immuntherapie. , 2022, , 53-58.		0
343	Impact of Blinatumomab Treatment on Bone Marrow Function in Patients with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia. <i>Cancers</i> , 2021, 13, 5607.	1.7	3
344	T Cell Bispecific Antibodies: An Antibody-Based Delivery System for Inducing Antitumor Immunity. <i>Pharmaceuticals</i> , 2021, 14, 1172.	1.7	13
346	Real-World Multicenter Experience in Tumor Debulking Prior to Blinatumomab Administration in Adult Patients With Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia. <i>Frontiers in Oncology</i> , 2021, 11, 804714.	1.3	9
350	Pediatric patients with acute lymphoblastic leukemia treated with blinatumomab in a real-world setting: Results from the NEUF study. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29562.	0.8	8
351	The Next Wave of Novel Agents in Aggressive B-Cell Lymphoma: Highlights From SOHO 2021. <i>Journal of the Advanced Practitioner in Oncology</i> , 2022, 13, 34-36.	0.2	0
352	Haematopoietic Stem Cell Transplantation in Adolescents and Young Adults With Acute Lymphoblastic Leukaemia: Special Considerations and Challenges. <i>Frontiers in Pediatrics</i> , 2021, 9, 796426.	0.9	4
353	Chemotherapy Resistance in B-ALL with Cryptic <i>NUP214-ABL1</i> Is Amenable to Kinase Inhibition and Immunotherapy. <i>Oncologist</i> , 2022, 27, 82-86.	1.9	5
354	The treatment landscape for Relapsed Refractory B Acute Lymphoblastic Leukaemia (ALL). <i>Leukemia and Lymphoma</i> , 2022, , 1-10.	0.6	0
356	Blinatumomab as a Bridge Therapy for Hematopoietic Stem Cell Transplantation in Pediatric Refractory/Relapsed Acute Lymphoblastic Leukemia. <i>Cancers</i> , 2022, 14, 458.	1.7	10
357	Blinatumomab in Children and Adolescents with Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia: A Real-Life Multicenter Retrospective Study in Seven AIEOP (Associazione) Tj ETQq0 0 0 rgBT /Overlck 10 Tf 5		
358	Blinatumomab in pediatric relapsed/refractory B-cell acute lymphoblastic leukemia: RIALTO expanded access study final analysis. <i>Blood Advances</i> , 2022, 6, 1004-1014.	2.5	22

#	ARTICLE	IF	CITATIONS
359	Exploiting Natural Killer Cell Engagers to Control Pediatric B-cell Precursor Acute Lymphoblastic Leukemia. <i>Cancer Immunology Research</i> , 2022, 10, 291-302.	1.6	17
360	From Myth to Reality: Achieving a Second Remission in Acute Lymphoblastic Leukemia. , 2022, 19, .		0
363	Monoclonal Antibody-Based Treatment and Other New Agents for B-Lineage Acute Lymphoblastic Leukemia. , 2022, , 295-328.		2
364	A novel CD34-specific T-cell engager efficiently depletes acute myeloid leukemia and leukemic stem cells <i>in vitro&/i> and <i>in vivo&/i>. <i>Haematologica</i> , 2022, 107, 1786-1795.	1.7	5
365	Genetic correlates in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with Hyper-CVAD plus dasatinib or ponatinib. <i>Leukemia</i> , 2022, 36, 1253-1260.	3.3	9
366	Acute lymphoblastic leukaemia (ALL) things come to those who wait: 60Âyears of progress in the treatment of adult ALL. <i>British Journal of Haematology</i> , 2020, 191, 558-561.	1.2	2
367	Bispecific Antibodies for the Treatment of Neuroblastoma. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
368	Inotuzumab ozogamicin and blinatumomab sequential therapy for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Leukemia Research Reports</i> , 2022, 17, 100294.	0.2	1
369	Development of Bispecific Antibody for Cancer Immunotherapy: Focus on T Cell Engaging Antibody. <i>Immune Network</i> , 2022, 22, e4.	1.6	12
370	SWOG 1318: A Phase II Trial of Blinatumomab Followed by POMP Maintenance in Older Patients With Newly Diagnosed Philadelphia Chromosomeâ€Negative B-Cell Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2022, 40, 1574-1582.	0.8	44
372	Empathetic nursing with mindful cognitive therapy for fatigue, depression, and negative emotions in leukemia patients undergoing long-term chemotherapy. <i>World Journal of Clinical Cases</i> , 2022, 10, 1826-1833.	0.3	1
373	Dismal outcomes of patients with relapsed/refractory Philadelphia chromosomeâ€negative Bâ€cell acute lymphoblastic leukemia after failure of both inotuzumab ozogamicin and blinatumomab. <i>American Journal of Hematology</i> , 2022, 97, .	2.0	7
374	Impact of Circulating Tumor DNAâ€Based Detection of Molecular Residual Disease on the Conduct and Design of Clinical Trials for Solid Tumors. <i>JCO Precision Oncology</i> , 2022, 6, e2100181.	1.5	33
375	Very rare nearâ€haploid acute lymphoblastic leukemia resistant to immunotherapy and CARâ€T therapy in 19â€yearâ€old male patient. <i>Clinical Case Reports (discontinued)</i> , 2022, 10, e05545.	0.2	2
376	Resistance Mechanisms in Pediatric B-Cell Acute Lymphoblastic Leukemia. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3067.	1.8	6
377	Translating recent advances in the pathogenesis of acute myeloid leukemia to the clinic. <i>Genes and Development</i> , 2022, 36, 259-277.	2.7	19
378	SOHO State of the Art Updates and Next Questions: Novel Transplant and Post-Transplant Options in Acute Lymphoblastic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, , .	0.2	0
379	Controversies in the Treatment of Adolescents and Young Adults with Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. <i>Current Oncology Reports</i> , 2022, , 1.	1.8	0

#	ARTICLE	IF	CITATIONS
380	Clinical Value of Measurable Residual Disease in Acute Lymphoblastic Leukemia. Blood and Lymphatic Cancer: Targets and Therapy, 2022, Volume 12, 7-16.	1.2	9
381	Bispecific Antibody Expressed by an Oncolytic Herpes Simplex Virus Type 2 Can Transform Heterologous T Cells Into Uniform Tumor Killer Cells. Human Gene Therapy, 2022, 33, 649-663.	1.4	5
382	Immunotherapies in acute leukemia. Therapie, 2022, 77, 241-250.	0.6	3
383	Anticancer effects of a single intramuscular dose of a minicircle DNA vector expressing anti-CD3/CD20 in a xenograft mouse model. Molecular Therapy - Oncolytics, 2022, 24, 788-798.	2.0	3
384	High tumor burden before blinatumomab has a negative impact on the outcome of adult patients with B-cell precursor acute lymphoblastic leukemia. A real-world study by the GRAALL. Haematologica, 2022, , .	1.7	10
385	Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in Adults. Cancers, 2022, 14, 1805.	1.7	10
386	In-vivo T-cell depleted reduced-intensity conditioned allogeneic haematopoietic stem-cell transplantation for patients with acute lymphoblastic leukaemia in first remission: results from the prospective, single-arm evaluation of the UKALL14 trial. Lancet Haematology,the, 2022, 9, e276-e288.	2.2	12
387	Updates in the Management of Relapsed and Refractory Acute Lymphoblastic Leukemia: An Urgent Plea for New Treatments Is Being Answered!. JCO Oncology Practice, 2022, 18, 479-487.	1.4	17
388	Liquid biopsies for residual disease and recurrence. Med, 2021, 2, 1292-1313.	2.2	15
389	Targeting Solid Tumors with Bispecific T Cell Engager Immune Therapy. Annual Review of Cancer Biology, 2022, 6, 17-34.	2.3	23
390	MRD in adult Ph/<i>BCR-ABL</i>-negative ALL: how best to eradicate?. Hematology American Society of Hematology Education Program, 2021, 2021, 718-725.	0.9	6
391	Acute lymphoblastic leukemia in older adults: curtain call for conventional chemotherapy?. Hematology American Society of Hematology Education Program, 2021, 2021, 7-14.	0.9	5
392	SOHO State of the Art Updates and Next Questions: Mini-Hyper-CVD Combinations for Older Adults: Results of Recent Trials and a Glimpse into the Future. Clinical Lymphoma, Myeloma and Leukemia, 2021, , .	0.2	1
395	Clinical Development and Therapeutic Applications of Bispecific Antibodies for Hematologic Malignancies. Cancer Treatment and Research, 2022, 183, 287-315.	0.2	0
396	A Chemotherapy-free Regimen for Older Adults and Relapsed or Refractory B-ALL. , 2022, 19, .		2
397	Blinatumomab overcomes poor prognostic impact of measurable residual disease in pediatric high-risk first relapse B-cell precursor acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2022, 69, e29715.	0.8	10
398	Time to First Subsequent Salvage Therapy in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia Treated With Inotuzumab Ozogamicin in the Phase III INO-VATE Trial. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, e836-e843.	0.2	1
399	Nonclinical Pharmacokinetics and Pharmacodynamics Characterization of Anti-CD79b/CD3 T Cell-Dependent Bispecific Antibody Using a Surrogate Molecule: A Potential Therapeutic Agent for B Cell Malignancies. Pharmaceutics, 2022, 14, 970.	2.0	4

#	ARTICLE	IF	CITATIONS
400	Innovative Approaches to the Management of Acute Lymphoblastic Leukemia Across the Age Spectrum. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2022, 42, 584-594.	1.8	2
401	Targeting Apoptosis in ALL. Current Hematologic Malignancy Reports, 2022, , 1.	1.2	2
403	Monoclonal antibodies in frontline therapy of adult acute lymphoblastic leukemia: A step ahead. Medicina Clínica (English Edition), 2022, 158, 476-476.	0.1	0
404	High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse. Blood Advances, 2022, 6, 4006-4014.	2.5	37
405	<scp>VANDA</scp> regimen followed by blinatumomab leads to favourable outcome in patients with Philadelphia chromosome-negative B-precursor acute lymphoblastic leukaemia in first relapse. British Journal of Haematology, 2022, , .	1.2	2
407	Immunotherapy and Allogeneic Bone Marrow Transplantation in B Acute Lymphoblastic Leukemia: How to Sequence?. Clinical Hematology International, 0, , 1.	0.7	3
408	BCR::ABL1 tyrosine kinase inhibitors hamper the therapeutic efficacy of blinatumomab in vitro. Journal of Cancer Research and Clinical Oncology, 2022, 148, 2759-2771.	1.2	2
409	Therapeutic bispecific antibodies against intracellular tumor antigens. Cancer Letters, 2022, 538, 215699.	3.2	12
410	Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia in the Modern Era. Transplantation and Cellular Therapy, 2022, , .	0.6	3
411	Asparaginase in the Treatment of Acute Lymphoblastic Leukemia in Adults: Current Evidence and Place in Therapy. Blood and Lymphatic Cancer: Targets and Therapy, 0, Volume 12, 55-79.	1.2	14
412	The EHA Research Roadmap: Malignant Lymphoid Diseases. HemaSphere, 2022, 6, e726.	1.2	1
413	MRD in ALL: Optimization and Innovations. Current Hematologic Malignancy Reports, 2022, 17, 69-81.	1.2	6
414	Monoclonal antibodies: new chance in the management of B-cell acute lymphoblastic leukemia. Hematology, 2022, 27, 642-652.	0.7	11
415	New Therapeutic Strategies for Adult Acute Myeloid Leukemia. Cancers, 2022, 14, 2806.	1.7	15
416	Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. New England Journal of Medicine, 2022, 386, 2399-2411.	13.9	31
417	The current treatment approach to adolescents and young adults with acute lymphoblastic leukemia (AYA-ALL): challenges and considerations. Expert Review of Anticancer Therapy, 2022, 22, 845-860.	1.1	2
418	The current state of molecular profiling in gastrointestinal malignancies. Biology Direct, 2022, 17, .	1.9	5
419	Blinatumomab is associated with favorable outcomes in patients with B-cell lineage acute lymphoblastic leukemia and positive measurable residual disease at a threshold of 10 ⁻⁴ and higher. American Journal of Hematology, 2022, 97, 1135-1141.	2.0	6

#	ARTICLE	IF	CITATIONS
420	Comment on: Blinatumomab overcomes poor prognostic impact of measurable residual disease in pediatric high-risk first relapse B-cell precursor acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2023, 70, .	0.8	0
421	Clinical experience with frontline Hyper-CVAD-based regimens, including Hyper-CVAD plus ponatinib, in patients with acute lymphoblastic leukemia treated at a comprehensive cancer center. <i>Leukemia Research</i> , 2022, 119, 106885.	0.4	2
422	Use of Circulating Tumour DNA to Assess Minimal Residual Disease in Gastrointestinal Cancers. <i>Touch Reviews in Oncology & Haematology</i> , 2022, 18, 26.	0.1	0
423	Leveraging gene therapy to achieve long-term continuous or controllable expression of biotherapeutics. <i>Science Advances</i> , 2022, 8, .	4.7	7
424	Bispecific antibodies for the treatment of neuroblastoma. , 2022, 237, 108241.		3
425	Antibody variable region engineering for improving cancer immunotherapy. <i>Cancer Communications</i> , 2022, 42, 804-827.	3.7	15
426	Excellent removal of knob-into-hole bispecific antibody byproducts and impurities in a single-capture chromatography. <i>Bioresources and Bioprocessing</i> , 2022, 9, .	2.0	5
427	The safety of blinatumomab in pediatric patients with acute lymphoblastic leukemia: A systematic review and meta-analysis. <i>Frontiers in Pediatrics</i> , 0, 10, .	0.9	14
429	The pharmacology of blinatumomab: state of the art on pharmacodynamics, pharmacokinetics, adverse drug reactions and evaluation in clinical trials. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 0, , .	0.7	4
430	Efficacy and safety of blinatumomab in Chinese adults with Ph-negative relapsed/refractory B-cell precursor acute lymphoblastic leukemia: A multicenter open-label single-arm China registrational study. <i>Hematology</i> , 2022, 27, 917-927.	0.7	3
431	A phase two study of high dose blinatumomab in Richter's syndrome. <i>Leukemia</i> , 2022, 36, 2228-2232.	3.3	10
432	Bispecific Antibodies for the Treatment of Multiple Myeloma. <i>Current Hematologic Malignancy Reports</i> , 2022, 17, 286-297.	1.2	4
433	Safety and outcomes of maintenance therapy with third-generation tyrosine kinase inhibitor after allogeneic hematopoietic cell transplantation in Philadelphia chromosome positive acute lymphoblastic leukemia patients with T315I mutation. <i>Leukemia Research</i> , 2022, 121, 106930.	0.4	3
434	Top advances of the year: Pediatric oncology. <i>Cancer</i> , 2022, 128, 3593-3596.	2.0	0
435	Effective flow-through polishing strategies for knob-into-hole bispecific antibodies. <i>Bioresources and Bioprocessing</i> , 2022, 9, .	2.0	3
436	EXABS-136-ALL Certain Patients with ALL Still Need a Transplant. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, S47-S49.	0.2	0
437	EXABS-132-ALL Approach to Acute Lymphoblastic Leukemia in The Elderly. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, S34-S38.	0.2	0
438	Considerations for design, manufacture, and delivery for effective and safe T-cell engager therapies. <i>Current Opinion in Biotechnology</i> , 2022, 78, 102799.	3.3	8

#	ARTICLE	IF	CITATIONS
439	Long-Term Results of Allogeneic Stem Cell Transplantation in Adult Ph- Negative High-Risk Acute Lymphoblastic Leukemia. <i>Transplantation and Cellular Therapy</i> , 2022, , .	0.6	5
440	Allogeneic hematopoietic stem cell transplantation for acute lymphoblastic leukemia: current status and future directions mainly focusing on a Chinese perspective. <i>Expert Review of Hematology</i> , 2022, 15, 789-803.	1.0	3
441	Case Analysis in Drug Approval by FDA/EMA Using Real-World Data/Real-World Evidence. , 2022, 14, 133-143.		0
442	Targeted Treatment and Immunotherapy in High-risk and Relapsed/ Refractory Pediatric Acute Lymphoblastic Leukemia. <i>Current Pediatric Reviews</i> , 2023, 19, 150-156.	0.4	1
443	A Probody T Cellâ€Engaging Bispecific Antibody Targeting EGFR and CD3 Inhibits Colon Cancer Growth with Limited Toxicity. <i>Cancer Research</i> , 2022, 82, 4288-4298.	0.4	13
445	Therapeutic Advances in Immunotherapies for Hematological Malignancies. <i>International Journal of Molecular Sciences</i> , 2022, 23, 11526.	1.8	6
446	Hyper-CVAD-Based Stem Cell Microtransplant as Post-Remission Therapy in Acute Lymphoblastic Leukemia. <i>Stem Cells Translational Medicine</i> , 2022, 11, 1113-1122.	1.6	1
447	Blinatumomab plus hyper-CVAD: the prelude to a new era in acute lymphocytic leukaemia. <i>Lancet Haematology</i> ,the, 2022, 9, e864-e865.	2.2	1
448	Hyper-CVAD and sequential blinatumomab for newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: a single-arm, single-centre, phase 2 trial. <i>Lancet Haematology</i> ,the, 2022, 9, e878-e885.	2.2	23
449	Association of hematologic response and assay sensitivity on the prognostic impact of measurable residual disease in acute myeloid leukemia: a systematic review and meta-analysis. <i>Leukemia</i> , 2022, 36, 2817-2826.	3.3	14
451	Measurable residual disease in acute lymphoblastic leukemia: How low is low enough?. <i>Best Practice and Research in Clinical Haematology</i> , 2022, 35, 101407.	0.7	2
452	Factors Affecting the Cancer Immunotherapeutic Efficacy of T Cell Bispecific Antibodies and Strategies for Improvement. <i>Immunological Investigations</i> , 2022, 51, 2176-2214.	1.0	5
453	When will chemotherapy be replaced in upfront induction therapy for adult acute lymphoblastic leukemia (ALL)?. <i>Best Practice and Research in Clinical Haematology</i> , 2022, 35, 101404.	0.7	0
454	Current landscape and future directions of bispecific antibodies in cancer immunotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	36
455	Dasatinib/prednisone induction followed by blinatumomab/dasatinib in Ph+ acute lymphoblastic leukemia. <i>Blood Advances</i> , 2023, 7, 1279-1285.	2.5	9
456	Neurotoxicity with blinatumomab in combination with intrathecal methotrexate therapy. <i>Leukemia and Lymphoma</i> , 0, , 1-4.	0.6	2
457	Immunotherapy approaches for hematological cancers. <i>IScience</i> , 2022, 25, 105326.	1.9	9
458	Reliable Flow-Cytometric Approach for Minimal Residual Disease Monitoring in Patients with B-Cell Precursor Acute Lymphoblastic Leukemia after CD19-Targeted Therapy. <i>Cancers</i> , 2022, 14, 5445.	1.7	6

#	ARTICLE	IF	CITATIONS
459	Marker fÃ¼r minimale Resterkrankung: Minimal Residual Disease. Springer Reference Medizin, 2022, , 1-8.	0.0	0
461	Modern Advances in CARs Therapy and Creating a New Approach to Future Treatment. International Journal of Molecular Sciences, 2022, 23, 15006.	1.8	4
462	Efficacy and Safety of Blinatumomab for the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: A Systemic Review and Meta-Analysis. Clinical Lymphoma, Myeloma and Leukemia, 2023, 23, e139-e149.	0.2	2
463	Optimal Timing of Blinatumomab for the Treatment of B-Acute Lymphoblastic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2022, , .	0.2	0
464	Cancer Immunotherapy Beyond Checkpoint Blockade. JACC: CardioOncology, 2022, 4, 563-578.	1.7	1
465	Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia. Blood Cancer Journal, 2022, 12, .	2.8	5
466	PAX5 epigenetically orchestrates CD58 transcription and modulates blinatumomab response in acute lymphoblastic leukemia. Science Advances, 2022, 8, .	4.7	5
467	Central Nervous System Prophylaxis and Treatment in Acute Leukemias. Current Treatment Options in Oncology, 2022, 23, 1829-1844.	1.3	3
468	Blinatumomab in Relapsed/Refractory Burkitt Lymphoma. Cancers, 2023, 15, 44.	1.7	2
469	Measurable residual disease in acute lymphoblastic leukemia: methods and clinical context in adult patients. Haematologica, 2022, 107, 2783-2793.	1.7	12
470	The emerging scenario of immunotherapy for T-cell Acute Lymphoblastic Leukemia: advances, challenges and future perspectives. Experimental Hematology and Oncology, 2023, 12, .	2.0	7
471	Post-Hematopoietic Cell Transplantation Relapsed Acute Lymphoblastic Leukemia: Current Challenges and Future Directions. OncoTargets and Therapy, 0, Volume 16, 1-16.	1.0	1
472	Real-world use of blinatumomab in adult patients with B-cell acute lymphoblastic leukemia in clinical practice: results from the NEUF study. Blood Cancer Journal, 2023, 13, .	2.8	3
473	Bispecific Antibody Format and the Organization of Immunological Synapses in T Cell-Redirecting Strategies for Cancer Immunotherapy. Pharmaceutics, 2023, 15, 132.	2.0	2
474	Combining targeted DNA repair inhibition and immune-oncology approaches for enhanced tumor control. Molecular Cell, 2023, 83, 660-680.	4.5	10
475	Cellular and Vaccine-Based Immunotherapy for Hematologic Malignancies. , 2023, , .		0
476	Bispecific Antibodies in Targeted Cancer Immunotherapy. , 2023, , 1-46.		1
477	Infectious complications during monoclonal antibodies treatments and cell therapies in Acute Lymphoblastic Leukemia. Clinical and Experimental Medicine, 0, , .	1.9	0

#	ARTICLE	IF	CITATIONS
478	Sequencing <scp>antigenâ€targeting</scp> antibodies and cellular therapies in adults with relapsed/refractory <scp>Bâ€cell</scp> acute lymphoblastic leukemia. American Journal of Hematology, 2023, 98, 666-680.	2.0	3
479	TRYBEÂ®: an Fc-free antibody format with three monovalent targeting arms engineered for long in vivo half-life. MAbs, 2023, 15, .	2.6	1
480	Optimal Use of Novel Immunotherapeutics in B-Cell Precursor ALL. Cancers, 2023, 15, 1349.	1.7	0
481	Bispecific T-Cell Engagers Therapies in Solid Tumors: Focusing on Prostate Cancer. Cancers, 2023, 15, 1412.	1.7	5
482	Blinatumomab therapy for B cell acute lymphoblastic leukemia accompanied by persistent or relapsed low-level MRD prior to hematopoietic stem cell transplantation in Chinese children: a case series. Bulletin of the National Research Centre, 2023, 47, .	0.7	0
483	Low leukemia burden improves blinatumomab efficacy in patients with relapsed/refractory Bâ€cell acute lymphoblastic leukemia. Cancer, 2023, 129, 1384-1393.	2.0	4
484	Translational advances in the treatment of childhood acute lymphoblastic leukemia: narrative review of current and emerging molecular and immunotherapies. Translational Pediatrics, 2023, 12, 487-502.	0.5	2
485	The role of blinatumomab in the treatment of B-cell relapses of acute lymphoblastic leukemia in children: own experience. Pediatric Hematology/Oncology and Immunopathology, 2023, 22, 62-72.	0.1	0
486	Targeting Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML): Moving beyond Prognostication. International Journal of Molecular Sciences, 2023, 24, 4790.	1.8	5
487	Approach to the Treatment of Philadelphia Chromosome-Negative B-cell ALL in Older Adults: Is Age Becoming just a Number?. Current Hematologic Malignancy Reports, 0, , .	1.2	0
488	The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades. Journal of Hematology and Oncology, 2023, 16, .	6.9	18
489	Cardiotoxicities of Novel Therapies in Hematologic Malignancies: Chimeric Antigen Receptor T-Cell Therapy and Bispecific T-Cell Engager Therapy. JCO Oncology Practice, 0, , .	1.4	0
490	Venetoclax and blinatumomab based chemotherapy-free treatment in a patient with Philadelphia chromosome-negative acute lymphoblastic leukemia. Annals of Hematology, 2023, 102, 1275-1277.	0.8	0
491	Using immunotherapy and novel trial designs to optimise front-line therapy in adult acute lymphoblastic leukaemia: breaking with the traditions of the past. Lancet Haematology,the, 2023, 10, e382-e388.	2.2	7
492	Specific causes of excess late mortality and association with modifiable risk factors among survivors of childhood cancer: a report from the Childhood Cancer Survivor Study cohort. Lancet, The, 2023, 401, 1447-1457.	6.3	28
493	Immunotherapy for Acute Leukemia. , 2022, , 1-41.		0
500	The clinical application of immuno-therapeutics. , 2024, , 237-288.e7.		0
501	Current applications of biomolecules in biopharmaceuticals and drug discovery. , 2023, , 439-466.		0

#	ARTICLE	IF	CITATIONS
502	Introduction about monoclonal antibodies. , 2023, , 1-38.		1
523	New monoclonal antibodies for the treatment of acute lymphoblastic leukemia. , 2024, , 165-192.		0
525	In the Pipeline“Emerging Therapy for ALL. , 2023, , 353-394.		0
526	Flow Cytometric Techniques in the Diagnosis and Monitoring of Acute Leukaemias. , 2023, , 47-59.		0
527	Management of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia (Ph-Like ALL). , 2023, , 311-327.		0
528	Management of Philadelphia Chromosome-positive Acute Lymphoblastic Leukaemia. , 2023, , 289-310.		0
529	Immunotherapeutic Targeting of AML. , 2023, , 175-191.		0
537	Case Report: Blinatumomab as upfront consolidation and maintenance therapy in a pediatric patient with high-risk B-cell acute lymphoblastic leukemia. Frontiers in Oncology, 0, 13, .	1.3	1
552	New immune cell engagers for cancer immunotherapy. Nature Reviews Immunology, 0, , .	10.6	0
559	Successful treatment of a B/T MPAL patient by chemo-free treatment with venetoclax, azacitidine, and blinatumomab. Annals of Hematology, 2024, 103, 1397-1402.	0.8	0